Haeberlein SB, Gheuens S, Chen T, et al. Aducanumab 36-month data from PRIME: a randomized, double-blind, placebocontrolled phase 1b study in patients with prodromal or mild Alzheimer’s disease. AAN 2018, S2.004.
ECTRIMS 2018
okt 2018
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen
aug 2021 | Hoofdpijn